Drug Search Results
More Filters [+]

Vofopitant

Alternative Names: vofopitant, gr205171
Latest Update: 2023-09-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vofopitant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Insomnia|Stress Disorders, Post-Traumatic

Phase 1: Bipolar Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00907985

P1

Terminated

Bipolar Disorder

2010-06-10

06-M-0253

P2

Completed

Stress Disorders, Post-Traumatic

2009-06-01

2007-004035-35

P2

Completed

Insomnia

2008-05-07

NKI110334

P2

Completed

Insomnia

2008-05-07

Recent News Events